Omics Techniques in Fatty Liver Disease - Trial NCT05907408
Access comprehensive clinical trial information for NCT05907408 through Pure Global AI's free database. This phase not specified trial is sponsored by Universidade Federal do Rio de Janeiro and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Universidade Federal do Rio de Janeiro
Timeline & Enrollment
N/A
Jul 01, 2023
Dec 31, 2023
Primary Outcome
Steatosis, without fibrosis or inflammation,Steatohepatitis, with fibrosis
Summary
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in
 Western countries and one of the leading causes of liver transplantation in the world. Its
 spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive
 fibrosis due to inflammation and cellular injury. The reasons why patients with the same
 degree of steatosis have different evolutions are not sufficiently known. The objective of
 this project is to identify biomarkers that predict disease progression, using omics
 techniques, which can serve to develop new therapeutic strategies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05907408
Non-Device Trial